# PROGRESS — LUCID100 slot 46 (DOI 10.1080/09553002.2025.2607004)

Subagent run: 2026-06-09 14:12–14:18 CDT, session `agent:main:subagent:160b484e-…`, host CherryRd.

## Checklist
- [x] Locate row in `LUCID100_SOLID_MASTER_QA.tsv` (line 100, Wave 5, queue 14, id 77)
- [x] Create working folder `lucid100-methylation-ddr-chronic-lowdose/` under `/Users/stevens/Dropbox/REPLICATE-PROJECT/LUCID-replications/`
- [x] Metadata harvest: Semantic Scholar, Unpaywall, OpenAlex, EuropePMC, PubMed, figshare
- [x] Confirm OA status = **closed** (no preprint, no repo copy, no PMC)
- [x] Locate + download CC BY 4.0 supplement (figshare 31324581 → `irab_a_2607004_sm4756.docx`, md5 verified)
- [x] Extract supplement text (`supplementary_sm4756_text.txt`)
- [x] Write `artifacts/MANIFEST.json`
- [x] Write minimal smoke script (`scripts/smoke_primer_check.py`)
- [x] Run smoke script and emit `notes/smoke_results.json`
- [x] Write `FIRST_PASS_REPORT.md` with explicit NO-GO verdict + QA retag recommendation
- [x] Write `NO_GO_REPORT.md` (same verdict, short form)
- [x] Update `memory/subagent-progress/lucid100-slot-46-methylation-ddr-chronic-lowdose.json`

## Blockers
- **Closed access** at the publisher (Taylor & Francis). Full text not needed to issue NO-GO — the abstract + methods + supplement give us the cohort size, panel, statistical claim, and confirm no public per-sample data exists.
- **No public per-sample data** anywhere (EuropePMC `hasSuppl=N`, Unpaywall closed, OpenAlex no repo, no GEO/SRA/ENA/Zenodo/dbGaP accessions in the metadata).

## Next actions (out of scope for this slot, logged for the curator)
1. **QA file retag:** change col 12 (`Replication target`) for line 100 from `omics/signature replication` → `wet-lab pilot, closed-access — NO-GO (in-silico)`; keep KEEP verdict, but mark replication path as scoping-only.
2. **Optional follow-on (separate slot):** cross-mine public 450K/EPIC methylation datasets on chronic LDIR cohorts (Mayak, Techa, A-bomb survivors, radon miners) for cumulative-dose-correlated hypermethylation at the RAD23B/DNMT3A/MRE11A/BRCA1 promoters reported here.
3. **Skip:** author contact, ResearchGate scraping, paid endpoints.
